Acceleron’s Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases Acceleron Pharma, Inc click to be linked ., a biopharmaceutical firm developing novel therapeutics that modulate the development of cells and tissues including red bloodstream cells, bone, and muscle, today announced preliminary outcomes from the ACE-031 Phase 1 single dose clinical trial demonstrating that ACE-031 increased lean muscle mass and muscle quantity. The total results from this randomized, placebo-controlled study were shown at the 14th International Congress of the global globe Muscle Society in Geneva, Switzerland.D., Chief Medical Officer at Acceleron.2 percent decrease in lean body mass at day 57 compared to a 2.4 percent upsurge in subjects receiving 1 mg/kg ACE-031 and a 2.6 percent increase in subjects receiving 3 mg/kg ACE-031 Subjects given single dosages of placebo acquired a 0.2 percent reduction in muscle quantity assessed by MRI at day time 29 compared to a 3.D., CEO of Acceleron.
In line with this and to be able to accelerate access to anti-retroviral medicines, the ongoing organization has initiated non-assert declarations in May 2007, well before the thought of the UNITAID patent pool was conceived. The declarations have been welcomed by all stakeholders including NGOs such as medicines sans frontieres, affected individual organisations and the press . The non-assert declaration means that the company won’t enforce its patent rights against the agreement partner. The company has additional waived the provision of a nominal royalty fee beneath the access policy so the partnering companies can provide you with the nevirapine-containing drugs without any obligations to Boehringer Ingelheim. This goes far beyond the conditions of the patent pool under dialogue currently.